Eli Lilly has requested Europe's medicines regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said on Friday. Last month, the regulator had rejected the drug, Kisunla, ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Lilly’s neurodegeneration portfolio is anchored by the Alzheimer’s drug Kisunla, which received FDA approval last July. That antibody drug was internally discovered and developed within Lilly.

A world-leading experimental dementia drug designed to prevent the disease before it begins will be trialled in Australia for ...

A new study has found that a common class of medications could dramatically decrease the risk of developing the neurodegenerative disorder.

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

When David Ricks became CEO of Eli Lilly, he faced the usual pressures of making the right, albeit risky, bets on the next ...

Officials from the Indianapolis-based drugmaker said the Lilly Medicine Foundry will help streamline the process of ...